Fig 1: Potential anti-tumor treatment by targeting the PSR-STAT3-JMJD3 axis. After treated with MERTK inhibitor (UNC569, 20 mg/kg/day), a STAT3 inhibitor (S3I-201, 5 mg/kg/day), a JMJD3 inhibitor (GSK-J4, 0.5 mg/kg/day), or an anti-TIM4 antibody (5 mg/kg/3 days). Mice bearing CT26 mouse peritoneal tumor were sacrificed. Tumor weight (A-D) and ascites volume (E-H) was recorded. Percentages of CD206+ macrophages in ascites (gating from CD45+CD11b+ F4/80+ cells) are shown by flow cytometry (I-L). The data are presented as the mean ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001, calculated using a two-tailed Student's t-testAbbreviations: M?, macrophage; MERTK, C-MER proto-oncogene tyrosine kinase; JMJD3, Jumonji domain-containing protein 3; STAT3, Signal Transducer and Activator of Transcription 3; TIM 4, T-cell immunoglobin mucin 4; SEM, standard error of mean.